Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Abstract This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin—can be explained...

Full description

Bibliographic Details
Main Authors: Hiromi Sato, Ayana Ishikawa, Hideki Yoshioka, Ryota Jin, Yamato Sano, Akihiro Hisaka
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
Pharmacometrics
SGLT2 inhibitor
Model-based meta-analysis
Diabetes
Online Access:https://doi.org/10.1038/s41598-024-76256-6

Internet

https://doi.org/10.1038/s41598-024-76256-6

Similar Items